Appendix Table 1. Treatments of the COVID-19 patients.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variables | All patients(N=154) | Survivors(N=102) | Deaths(N=52) | *P* |
| Antiviral therapy | 128 (83.12) | 86 (84.31) | 42 (80.77) | 0.579 |
| Antibiotics | 149 (98.03) | 97 (95.10) | 52 (100.00) | 0.168 |
| Glucocorticoid therapy | 136 (88.31) | 87 (85.29) | 49 (94.23) | 0.103 |
| Immunoglobulin | 65 (42.21) | 41 (40.20) | 24 (46.15) | 0.501 |
| Vasoactive amines | 36 (23.38) | 0 (0.00) | 36 (69.23) | **<0.001** |
| Oxygen therapy | 154 (100.00) | 102 (100.00) | 52 (100.00) | NA |
| High flow nasal cannula | 27 (17.53) | 24 (23.53) | 3 (5.77) | **0.006** |
| Mechanical ventilation | 65 (42.21) | 16 (24.62) | 49 (96.63) | **<0.001** |
| Non-invasive | 23 (14.94) | 11 (10.78) | 12 (23.08) | **0.043** |
| Invasive | 42 (27.27) | 5 (4.90) | 37 (71.15) | **<0.001** |
| Continuous renal replacement therapy | 15 (9.74) | 1 (0.98) | 14 (26.92) | <0.001 |